; and (iii) the best price determined under section 1927(c)(1)(C) for such drug for the most recent rebate period (as defined in section 1927(k)(8)) applicable to such first plan year of such negotiated price period. (C) Identification of negotiation drug groupings (i) In general For each negotiation year, the Secretary shall, during the previous year, in accordance with the subsequent clauses of this subparagraph, and pursuant to rulemaking, identify covered part D drugs for which negotiations under subparagraph (A) shall be conducted during such negotiation year. In this subsection, all such covered part D drugs so identified for a negotiation year are collectively referred to as the negotiation drug grouping, with respect to such year. (ii) Identification of prioritized drugs In carrying out clause (i), except as provided under clause (iii), the Secretary may not identify for inclusion within the negotiation drug grouping with respect to a negotiation year, a covered part D drug that is not a drug prioritized pursuant to subparagraph (D) before all covered part D drugs that are so prioritized have been identified for inclusion in such grouping or in a negotiation drug grouping with respect to a previous negotiation year for which the negotiated price period has not expired. (iii) Drug inclusions for price renegotiations In the case of a covered part D drug that is identified as included in a negotiation drug grouping under this subparagraph, with respect to a negotiation year, such covered part D drug shall be identified as included within the negotiation drug grouping for each subsequent third negotiation year. (iv) Reasonable notification The Secretary shall carry out this subparagraph in such manner as to provide for public notification of the negotiation drug grouping identified with respect to a negotiation year within a reasonable period before the beginning of such negotiation year. (D) Prioritization For purposes of subparagraph (C)(ii), for a negotiation drug grouping, with respect to a negotiation